Research background · Updated November 1, 2026
IGF-1 LR3 Research: Publications, Study Types and Background
Short answer
IGF-1 LR3 is listed as analogue of human insulin-like growth factor I: arginine at position 3 and a 13-residue N-terminal extension, 83 amino acids. As of November 1, 2026, PubMed indexes 90 records matching IGF-1 LR3, the earliest from 1992; 9 were published in 2021–2025 and 2 are reviews. ClinicalTrials.gov lists 0 registered studies matching the compound.
- PubMed records
- 90
- Earliest record
- 1992
- Published 2021–2025
- 9
- Reviews
- 2
- Animal-only studies
- 59
- Registered studies
- 0
Publications per year, 2006–2025
13 records in 2016–2025 against 14 in 2006–2015; the busiest year was 2006, with 3.
See the numbers
| Year | PubMed records |
|---|---|
| 2006 | 3 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 0 |
| 2014 | 1 |
| 2015 | 0 |
| 2016 | 0 |
| 2017 | 0 |
| 2018 | 0 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 3 |
Study types
| All PubMed records | 90 |
|---|---|
| Reviews | 22% |
| Animal studies (no human subjects indexed) | 5966% |
| Indexed as clinical trials | 00% |
| Registered on ClinicalTrials.gov | 0 |
Categories overlap and follow PubMed’s own indexing; recent records may not be indexed yet.
Primary research directions
What 7 of the most-cited and most recent IGF-1 LR3 papers report, in their own authors’ terms. Each line links the paper it came from.
This narrative review describes IGF-1 LR3 among unregulated peptides marketed as research compounds that act on the GH-IGF-1 axis, stratifies such peptides by strength of evidence, and summarizes reported adverse effects, including endocrine-metabolic disturbances and biologically plausible but unconfirmed mitogenic concerns.
ReviewDominikowski A 2026Frontiers in endocrinologyPMID 42395176
This review summarizes IGF-I and IGF-II receptor and gene expression in the mammalian small intestine, and describes animal studies in which LR3-IGF-I affected the small intestine similarly to IGF-I, although with a higher potency.
ReviewMacDonald RS 1999Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolismePMID 10226789
In fetal sheep, LR3 IGF-1 did not stimulate cardiomyocyte hypertrophy but was associated with a lower percentage of binucleated cells; in cultured fetal sheep cardiomyocytes it increased BrdU uptake, an effect abolished when ERK or PI3K signaling was blocked.
AnimalsSundgren NC 2003American journal of physiology. Regulatory, integrative and comparative physiologyPMID 12947030
In cultured bovine granulosa cells, the LR3 IGF-I analogue increased output of inhibin A, activin A, follistatin and estradiol, with modest increases in progesterone and cell number; the authors suggest IGF and FSH may selectively raise activin tone as part of estradiol induction.
CellsGlister C 2001Biology of reproductionPMID 11566722
In MCF7 breast cancer cells, Long R3 IGF-I, an analogue with greatly reduced affinity for IGF binding proteins, was a more potent inhibitor of IGFBP-3-induced and ICI-induced apoptosis than IGF-I, which the authors interpret as IGFBP-3 acting by reducing ligand bioavailability.
CellsNickerson T 1997Biochemical and biophysical research communicationsPMID 9299428
In chick embryos, long R3 IGF-I and des(1-3) IGF-I, IGF-I variants with reduced affinity for IGF binding proteins, were reported to enhance motoneuron survival during the period of developmental neuronal death to a degree equal to that seen with IGF-I.
AnimalsNeff NT 1993Journal of neurobiologyPMID 8301266
In cultured human dermal fibroblasts, the authors report that Long-R3-IGF-I, which has little affinity for IGF binding proteins, was approximately 20-fold more potent than IGF-I in a growth assay and was unaffected by added IGFBP-3.
CellsYateman ME 1993The Journal of endocrinologyPMID 7684061
Most-studied topics
The Medical Subject Headings (MeSH) PubMed indexers most often marked as a main topic, across 90 of the 90 records. They describe what the literature is about, not what IGF-1 LR3 does.
- Insulin-Like Growth Factor I65 papers
- Insulin-Like Growth Factor Binding Protein 311 papers
- Granulosa Cells11 papers
- Insulin-Like Growth Factor Binding Proteins9 papers
- Growth Hormone7 papers
- Insulin-Like Growth Factor II7 papers
- Somatomedins6 papers
- Insulin5 papers
Key papers
Earliest indexed record
Harel Z (1992). Endocrinology.
PMID 1639021Most-cited paper · 209 citations
Neff NT (1993). Journal of neurobiology.
PMID 8301266Most-cited #2 · 161 citations
Haluska P (2006). Cancer research.
PMID 16397250Most-cited #3 · 137 citations
Nickerson T (1997). Biochemical and biophysical research communications.
PMID 9299428
Citation counts from NIH iCite, among the 90 records sampled. Titles are left out; open each record on PubMed to read it.
Identity
| Synonyms and codes | Long R3 IGF-I, Long-(Arg3) insulin-like growth factor-I |
|---|---|
| Description | Analogue of human insulin-like growth factor I: arginine at position 3 and a 13-residue N-terminal extension, 83 amino acids |
| Supplied form | Lyophilized powder |
| CAS number | 143045-27-6 |
| UNII | M9L22Y19H9 |
As published by Vanta Labs, with its sources, on the IGF-1 LR3 page.
How these numbers were counted
- PubMed search, run November 1, 2026:
"LR3-IGF-I"[tiab] OR "Long R3 IGF-I"[tiab] OR "Long R3 IGF-1"[tiab] OR "IGF-1 LR3"[tiab] OR "LR3 IGF-1"[tiab]re-run it. Study types add PubMed’s own filters (review, clinical trial, animals not humans). - Topics: MeSH major-topic headings counted across up to 400 of the matching records; headings for study set-up (species, sex, age) are left out.
- Citations: NIH iCite citation counts for the same records.
- ClinicalTrials.gov search:
"IGF-1 LR3"re-run it. Any phase, any status.
This page reports what has been published and what papers say they found, with each source linked. It gives no dosing or usage information, and nothing here is a reason to use IGF-1 LR3 outside a laboratory.
Wholesale supply
IGF-1 LR3 for research, documented lot by lot.
1mg vials, with a published report printing 99.793% HPLC purity. Every wholesale lot comes with its certificate of analysis, and your quote names the lot. Pricing on inquiry.
IGF-1 LR3 research questions
How much research has been published on IGF-1 LR3?
PubMed indexes 90 records matching IGF-1 LR3 (searched November 1, 2026), including 2 reviews and 0 records indexed as clinical trials. 9 were published in the five years 2021–2025.
When was IGF-1 LR3 first described in the literature?
The earliest PubMed record matching IGF-1 LR3 is from 1992 (Harel Z, Endocrinology, PMID 1639021).
What topics does the IGF-1 LR3 literature cover?
The subject headings PubMed indexers most often marked as a main topic of IGF-1 LR3 papers are Insulin-Like Growth Factor I, Insulin-Like Growth Factor Binding Protein 3, Granulosa Cells, Insulin-Like Growth Factor Binding Proteins. These describe what the literature is about. Findings from individual papers, with their sources, are summarized on this page.
What is the regulatory status of IGF-1 LR3?
IGF-1 LR3 is not listed as an approved drug in the FDA's Drugs@FDA database (searched 24 September 2026).
Is IGF-1 LR3 sold for human use?
No. Vanta Foundry supplies it for laboratory research use only. Not for human or veterinary use, and not a drug, food, cosmetic or dietary supplement.
Where can I buy IGF-1 LR3 wholesale for research?
From the Vanta Foundry wholesale catalog: add it to your list, choose sizes and the number of vials, and send it on WhatsApp or by email. Every wholesale lot comes with a certificate of analysis.
Research materials supplied by Vanta Foundry are for laboratory research use only. They are not for human or veterinary use and are not drugs, foods, cosmetics or dietary supplements. Websites and payment processing are business services for research-supply brands.
All compounds: research peptide publication statistics.